Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2023 03:30 ET | Source: EsoCap AG

EsoCap completes patient recruitment in ACESO Phase II trial in eosinophilic esophagitis

EsoCap's novel targeted delivery platform is designed to increase mucosal contact time and drug deposition in the esophagus ESO-101, EsoCap's lead product candidate, consists of a capsule with a...
May 29, 2023 14:00 ET | Source: SPHERICAL INSIGHTS LLP

Global Barrett’s Esophagus Market Size To Grow USD 12.5 Billion By 2032 | CAGR of 6.4%

New York, United States , May 29, 2023 (GLOBE NEWSWIRE) -- The Global Barrett’s Esophagus Market Size is to grow from USD 6.7 billion in 2022 to USD 12.5 billion by 2032, at a Compound Annual Growth...
June 14, 2022 03:32 ET | Source: EsoCap AG

EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus

EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in ZurichEsoCap’s technology for the topical treatment of...
February 15, 2022 08:00 ET | Source: Stella Diagnostics, Inc. and SmallCapVoice.com

Stella Diagnostics CEO Discusses Competitive Advantage in Early Cancer Detection During Audio Interview with SmallCapVoice.com

AUSTIN, Texas, Feb. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Joe Abdo, CEO of Stella Diagnostics Inc. (OTC Pink: SLDX) (“the...
January 10, 2022 05:32 ET | Source: EsoCap AG

EsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagus

Licensing deal grants EsoCap exclusive access to Upadia’s monoclonal antibodies for a local therapy for Barrett’s esophagusBarrett’s esophagus, a disease of the esophagus with high unmet medical need,...
June 24, 2019 10:46 ET | Source: PAVmed Inc.

PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™

NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its...
November 29, 2018 07:30 ET | Source: PAVmed Inc.

PAVmed Subsidiary Lucid Diagnostics Files 510(k) Submission with FDA for EsoCheck™ Cell Collection Device

NEW YORK, Nov. 29, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
October 17, 2018 07:30 ET | Source: PAVmed Inc.

PAVmed Provides Business Update

NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on...
October 10, 2018 08:30 ET | Source: Interpace Diagnostics Group, Inc.

Interpace Diagnostics CEO Provides Corporate Update

PARSIPPANY, NJ, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) is pleased to provide a corporate update to shareholders on current business activities from its Chief...